Processing your request

please wait...

Case Page


Case Status:    DISMISSED    
On or around 11/04/2016 (Court's order of dismissal)

Filing Date: September 07, 2016

According to the law firm press release, on August 30, 2016, Montreal, Inc., a wholly-owned subsidiary of Pfizer, commenced a tender offer for Medivation shares scheduled to expire on September 27, 2016. If a sufficient number of Medivation shares are tendered, a second-step merger will be effectuated without a shareholder vote, and Montreal, Inc. will merge with and into Medivation, with Medivation continuing as a wholly-owned subsidiary of Pfizer.

Pursuant to the terms of the Merger Agreement, which was unanimously approved by the Board, Medivation shareholders stand to receive $81.50 per share in cash for each share they own. The complaint claims that this offer is inadequate in light of the Company's intrinsic value and long-term prospects and alleges that the Schedule 14D-9 Solicitation/Recommendation Statement (the "14D-9") provides materially incomplete and misleading information about the process leading up to the Board's decision to approve the Proposed Transaction and the valuation analyses performed by the Board's financial advisors, in violation of Sections 14(d)(4), 14(e), and 20(a) of the Exchange Act.

On November 4, 2016, this case was voluntarily dismissed.


Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: United States


Ticker Symbol: MDVN
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data

"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
COURT: N.D. California
DOCKET #: 16-CV-05154
JUDGE: Hon. William Alsup
DATE FILED: 09/07/2016
CLASS PERIOD END: 09/07/2016
  1. Faruqi & Faruqi LLP (Los Angeles)
  2. Monteverde & Associates PC
No Document Title Filing Date
—Reference Complaint Complaint Related Data is not available
—Related District Court Filings Data is not available